Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Amarin in 'strong position' against Health Net, says Piper Sandler » 10:35
01/26/21
01/26
10:35
01/26/21
10:35
AMRN

Amarin

$7.38 /

-0.17 (-2.25%)

, GSK

GlaxoSmithKline

$39.12 /

+0.21 (+0.54%)

, TEVA

Teva

$12.33 /

-0.065 (-0.52%)

Amarin (AMRN) yesterday…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMRN Amarin
$7.38 /

-0.17 (-2.25%)

GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

TEVA Teva
$12.33 /

-0.065 (-0.52%)

AMRN Amarin
$7.38 /

-0.17 (-2.25%)

01/25/21 Cantor Fitzgerald
Cantor says Amarin opportunity for Vascepa outside U.S. still 'underappreciated'
01/25/21 Piper Sandler
Piper Sandler reiterates 'conviction call' on Amarin into European decision
01/22/21 Cowen
Amarin remains undervalued under almost any scenario, says Cowen
01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

01/20/21 UBS
GlaxoSmithKline price target raised to 1,450 GBp from 1,440 GBp at UBS
01/20/21
Fly Intel: Top five analyst downgrades
01/20/21 Credit Suisse
GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
01/20/21 Credit Suisse
GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
TEVA Teva
$12.33 /

-0.065 (-0.52%)

12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
11/27/20 H.C. Wainwright
Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright
11/24/20 Oppenheimer
Teva initiated with a Perform at Oppenheimer
11/23/20 Citi
Citi recommends pair trade of overweight Endo, underweight Teva
AMRN Amarin
$7.38 /

-0.17 (-2.25%)

GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

TEVA Teva
$12.33 /

-0.065 (-0.52%)

AMRN Amarin
$7.38 /

-0.17 (-2.25%)

GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

TEVA Teva
$12.33 /

-0.065 (-0.52%)

AMRN Amarin
$7.38 /

-0.17 (-2.25%)

GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

TEVA Teva
$12.33 /

-0.065 (-0.52%)

AMRN Amarin
$7.38 /

-0.17 (-2.25%)

GSK GlaxoSmithKline
$39.12 /

+0.21 (+0.54%)

TEVA Teva
$12.33 /

-0.065 (-0.52%)

Hot Stocks
Amarin expands Vascepa patent infringement suit to include Health Net » 10:32
01/26/21
01/26
10:32
01/26/21
10:32
AMRN

Amarin

$7.40 /

-0.15 (-1.99%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Amarin (AMRN) last night…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMRN Amarin
$7.40 /

-0.15 (-1.99%)

HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

AMRN Amarin
$7.40 /

-0.15 (-1.99%)

01/25/21 Cantor Fitzgerald
Cantor says Amarin opportunity for Vascepa outside U.S. still 'underappreciated'
01/25/21 Piper Sandler
Piper Sandler reiterates 'conviction call' on Amarin into European decision
01/22/21 Cowen
Amarin remains undervalued under almost any scenario, says Cowen
01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
HKMPF Hikma Pharmaceuticals
$0.00 /

+ (+0.00%)

01/25/21 Peel Hunt
Hikma Pharmaceuticals downgraded to Hold from Buy at Peel Hunt
01/05/21 Citi
Underlying trends for Hikma point to upside risks, says Citi
11/24/20 JPMorgan
Hikma Pharmaceuticals price target raised to 3,000 GBp from 2,400 GBp at JPMorgan
09/22/20 Morgan Stanley
Hikma Pharmaceuticals downgraded to Equal Weight from Overweight at Morgan Stanley
AMRN Amarin
$7.40 /

-0.15 (-1.99%)

AMRN Amarin
$7.40 /

-0.15 (-1.99%)

AMRN Amarin
$7.40 /

-0.15 (-1.99%)

AMRN Amarin
$7.40 /

-0.15 (-1.99%)

Hot Stocks
Humana unit partners in Primary Care announces growth plans » 09:23
01/26/21
01/26
09:23
01/26/21
09:23
HUM

Humana

$403.97 /

-1.5 (-0.37%)

Partners in Primary Care…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HUM Humana
$403.97 /

-1.5 (-0.37%)

HUM Humana
$403.97 /

-1.5 (-0.37%)

01/13/21 Deutsche Bank
DaVita price target raised to $150 from $105 at Deutsche Bank
01/06/21 Argus
Humana price target raised to $450 from $430 at Argus
01/04/21
Fly Intel: Top five analyst upgrades
01/04/21
Humana upgraded to Outperform at RBC Capital on above-average MA growth
HUM Humana
$403.97 /

-1.5 (-0.37%)

HUM Humana
$403.97 /

-1.5 (-0.37%)

HUM Humana
$403.97 /

-1.5 (-0.37%)

Recommendations
Teladoc price target raised to $330 from $260 at BTIG » 08:51
01/26/21
01/26
08:51
01/26/21
08:51
TDOC

Teladoc

$286.92 /

+23.74 (+9.02%)

, UNH

UnitedHealth

$347.99 /

+0.09 (+0.03%)

BTIG analyst David Larsen…

BTIG analyst David Larsen raised the firm's price target on Teladoc (TDOC) to $330 from $260 and keeps a Buy rating on the shares. The analyst notes that the stock's recent strength is driven by several factors, including the indication made by UnitedHealth (UNH) last week that it would work with multiple tele-health vendors, the recent spike in COVID cases driving the need for tele-health options, and the commentary by UnitedHealth about the durability of tele-health beyond the pandemic.

ShowHide Related Items >><<
UNH UnitedHealth
$347.99 /

+0.09 (+0.03%)

TDOC Teladoc
$286.92 /

+23.74 (+9.02%)

TDOC Teladoc
$286.92 /

+23.74 (+9.02%)

01/19/21 JPMorgan
Teladoc remains top 2021 healthcare technology pick at JPMorgan
01/15/21 Benchmark
SOC Telemed initiated with a Buy at Benchmark
01/12/21 BTIG
Teladoc price target raised to $260 from $240 at BTIG
01/12/21 Piper Sandler
Teladoc visibility improving, fundamentals attractive, says Piper Sandler
UNH UnitedHealth
$347.99 /

+0.09 (+0.03%)

01/21/21 Deutsche Bank
UnitedHealth price target raised to $409 from $404 at Deutsche Bank
01/07/21 Wells Fargo
Change Healthcare downgraded to Equal Weight from Overweight at Wells Fargo
01/07/21 Cowen
Change Healthcare downgraded to Market Perform from Outperform at Cowen
01/07/21 Deutsche Bank
UnitedHealth price target raised to $404 from $359 at Deutsche Bank
UNH UnitedHealth
$347.99 /

+0.09 (+0.03%)

TDOC Teladoc
$286.92 /

+23.74 (+9.02%)

UNH UnitedHealth
$347.99 /

+0.09 (+0.03%)

TDOC Teladoc
$286.92 /

+23.74 (+9.02%)

UNH UnitedHealth
$347.99 /

+0.09 (+0.03%)

TDOC Teladoc
$286.92 /

+23.74 (+9.02%)

UNH UnitedHealth
$347.99 /

+0.09 (+0.03%)

TDOC Teladoc
$286.92 /

+23.74 (+9.02%)

Upgrade
Allogene Therapeutics upgraded to Buy from Hold at Stifel » 06:01
01/26/21
01/26
06:01
01/26/21
06:01
ALLO

Allogene Therapeutics

/

+

Stifel analyst Benjamin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALLO Allogene Therapeutics
/

+

ALLO Allogene Therapeutics
/

+

12/28/20 H.C. Wainwright
SpringsWorks Therapeutics price target raised to $87 from $73 at H.C. Wainwright
12/10/20 H.C. Wainwright
Allogene Therapeutics assumed with a Buy at H.C. Wainwright
11/24/20 BofA
Allogene Therapeutics initiated with a Buy at BofA
11/24/20 BofA
Allogene Therapeutics initiated with a Buy at BofA
ALLO Allogene Therapeutics
/

+

  • 02
    Jun
ALLO Allogene Therapeutics
/

+

Yesterday
On The Fly
Fly Intel: After-Hours Movers » 18:53
01/25/21
01/25
18:53
01/25/21
18:53
IPAR

Inter Parfums

$60.50 /

+1.41 (+2.39%)

, GGG

Graco

$74.74 /

-1.17 (-1.54%)

, FUL

H.B. Fuller

$50.80 /

-1.98 (-3.75%)

, WSFS

WSFS Financial

$46.04 /

-0.5 (-1.07%)

, HXL

Hexcel

$47.09 /

-1.235 (-2.56%)

, STLD

Steel Dynamics

$38.37 /

-0.35 (-0.90%)

, BDGE

Bridge Bancorp

$27.19 /

-0.08 (-0.29%)

, STAA

Staar Surgical

$89.69 /

-1.69 (-1.85%)

, IAC

IAC

$202.84 /

+1.83 (+0.91%)

, NBTX

Nanobiotix

$17.47 /

-1.25 (-6.68%)

, BCRX

BioCryst

$9.15 /

-0.06 (-0.65%)

, JJSF

J & J Snack Foods

$156.47 /

+3.58 (+2.34%)

, CR

Crane

$78.60 /

-2.15 (-2.66%)

, KRMD

Koru Medical

$5.13 /

-0.06 (-1.16%)

, QUMU

Qumu

$8.11 /

-0.32 (-3.80%)

, SEEL

Seelos Therapeutics

$2.65 /

+0.07 (+2.71%)

, CVAC

CureVac

$104.31 /

+2.31 (+2.26%)

, ASO

Academy Sports

$23.70 /

+1.28 (+5.71%)

Check out this evening's…

ShowHide Related Items >><<
WSFS WSFS Financial
$46.04 /

-0.5 (-1.07%)

STLD Steel Dynamics
$38.37 /

-0.35 (-0.90%)

STAA Staar Surgical
$89.69 /

-1.69 (-1.85%)

SEEL Seelos Therapeutics
$2.65 /

+0.07 (+2.71%)

NBTX Nanobiotix
$17.47 /

-1.25 (-6.68%)

KRMD Koru Medical
$5.13 /

-0.06 (-1.16%)

JJSF J & J Snack Foods
$156.47 /

+3.58 (+2.34%)

IPAR Inter Parfums
$60.50 /

+1.41 (+2.39%)

IAC IAC
$202.84 /

+1.83 (+0.91%)

HXL Hexcel
$47.09 /

-1.235 (-2.56%)

GGG Graco
$74.74 /

-1.17 (-1.54%)

FUL H.B. Fuller
$50.80 /

-1.98 (-3.75%)

CVAC CureVac
$104.31 /

+2.31 (+2.26%)

CR Crane
$78.60 /

-2.15 (-2.66%)

BDGE Bridge Bancorp
$27.19 /

-0.08 (-0.29%)

BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

ASO Academy Sports
$23.70 /

+1.28 (+5.71%)

IPAR Inter Parfums
$60.50 /

+1.41 (+2.39%)

12/02/20 DA Davidson
Inter Parfums price target lowered to $50 from $55 at DA Davidson
11/11/20 DA Davidson
Inter Parfums price target raised to $55 from $39 at DA Davidson
11/11/20 Citi
Inter Parfums price target raised to $56 from $46 at Citi
08/12/20 BWS Financial
Inter Parfums upgraded to Buy from Neutral at BWS Financial
GGG Graco
$74.74 /

-1.17 (-1.54%)

01/19/21 Jefferies
Graco upgraded to Buy from Hold at Jefferies
10/23/20 RBC Capital
Graco price target raised to $72 from $65 at RBC Capital
10/16/20 Berenberg
Graco initiated with a Hold at Berenberg
08/11/20
Fly Intel: Top five analyst upgrades
FUL H.B. Fuller
$50.80 /

-1.98 (-3.75%)

01/04/21 Baird
H.B. Fuller upgraded to Outperform, added to 2021 top picks at Baird
01/04/21 Baird
H.B. Fuller upgraded to Outperform from Neutral at Baird
12/18/20
Fly Intel: Top five analyst upgrades
12/18/20 Citi
H.B. Fuller upgraded to Buy from Neutral at Citi
WSFS WSFS Financial
$46.04 /

-0.5 (-1.07%)

04/01/20 Keefe Bruyette
WSFS Financial upgraded to Outperform from Market Perform at Keefe Bruyette
HXL Hexcel
$47.09 /

-1.235 (-2.56%)

01/21/21 Credit Suisse
Hexcel downgraded to Underperform from Neutral at Credit Suisse
01/21/21 Credit Suisse
Hexcel downgraded to Underperform from Neutral at Credit Suisse
12/15/20 KeyBanc
Hexcel downgraded to Sector Weight at KeyBanc
12/14/20 KeyBanc
Hexcel downgraded to Sector Weight from Overweight at KeyBanc
STLD Steel Dynamics
$38.37 /

-0.35 (-0.90%)

12/09/20 Morgan Stanley
Steel Dynamics initiated with an Overweight at Morgan Stanley
10/21/20 BMO Capital
Steel Dynamics price target raised to $35 from $32 at BMO Capital
09/18/20 BMO Capital
Steel Dynamics price target raised to $32 from $29 at BMO Capital
07/29/20 Deutsche Bank
Steel Dynamics price target raised to $31 from $27 at Deutsche Bank
BDGE Bridge Bancorp
$27.19 /

-0.08 (-0.29%)

12/16/20 Boenning & Scattergood
Bridge Bancorp downgraded to Neutral from Outperform at Boenning & Scattergood
11/13/20 DA Davidson
Bridge Bancorp upgraded to Buy from Neutral at DA Davidson
STAA Staar Surgical
$89.69 /

-1.69 (-1.85%)

01/19/21 Benchmark
Staar Surgical downgraded to Hold on valuation at Benchmark
01/19/21 Benchmark
Staar Surgical downgraded to Hold from Buy at Benchmark
11/09/20 Canaccord
Staar Surgical price target raised to $84 from $70 at Canaccord
10/26/20 Sidoti
Staar Surgical downgraded to Neutral from Buy at Sidoti
IAC IAC
$202.84 /

+1.83 (+0.91%)

01/25/21 Piper Sandler
IAC price target raised to $240 from $211 at Piper Sandler
01/14/21 Deutsche Bank
IAC price target raised to $230 from $165 at Deutsche Bank
01/12/21 Piper Sandler
IAC price target raised to $211 from $205 at Piper Sandler
01/08/21 Goldman Sachs
Goldman Sachs sees IAC news as positive for MGM Resorts
NBTX Nanobiotix
$17.47 /

-1.25 (-6.68%)

01/05/21 Evercore ISI
Nanobiotix initiated with an Outperform at Evercore ISI
01/05/21 UBS
Nanobiotix initiated with a Buy at UBS
BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

12/22/20 JMP Securities
BioCryst selloff today a buying opportunity, says JMP Securities
12/07/20 H.C. Wainwright
BioCryst price target raised to $14 from $13 at H.C. Wainwright
12/04/20 Piper Sandler
BioCryst receives on-time approval with 'clean' label, says Piper Sandler
11/23/20 Evercore ISI
BioCryst initiated with an Outperform at Evercore ISI
JJSF J & J Snack Foods
$156.47 /

+3.58 (+2.34%)

05/12/20 CL King
J & J Snack Foods upgraded to Buy from Neutral at CL King
CR Crane
$78.60 /

-2.15 (-2.66%)

01/07/21 Vertical Research
Crane upgraded to Buy with $97 price target at Vertical Research
01/07/21 DA Davidson
Crane cut to Neutral at DA Davidson on valuation
01/07/21 DA Davidson
Crane downgraded to Neutral from Buy at DA Davidson
10/07/20 DA Davidson
DA Davidson positive on Crane's Engineered Materials, PMT segments
KRMD Koru Medical
$5.13 /

-0.06 (-1.16%)

01/25/21 Piper Sandler
Koru Medical downgraded to Neutral from Overweight at Piper Sandler
11/04/20 Piper Sandler
Koru Medical earnings selloff a buying opportunity, says Piper Sandler
08/10/20 H.C. Wainwright
KORU Medical Systems initiated with a Buy at H.C. Wainwright
08/05/20 Piper Sandler
KORU Medical Systems price target raised to $14 from $12 at Piper Sandler
QUMU Qumu
$8.11 /

-0.32 (-3.80%)

07/15/20 Craig-Hallum
Qumu price target raised to $5 from $4 at Craig-Hallum
06/30/20 Craig-Hallum
Qumu upgraded to Buy at Craig-Hallum after merger agreement termination
06/30/20 Craig-Hallum
Qumu upgraded to Buy from Hold at Craig-Hallum
02/12/20
Qumu downgraded to Neutral from Buy at Dougherty
SEEL Seelos Therapeutics
$2.65 /

+0.07 (+2.71%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
CVAC CureVac
$104.31 /

+2.31 (+2.26%)

01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
12/10/20 Credit Suisse
CureVac downgraded to Underperform from Neutral at Credit Suisse
11/02/20 Piper Sandler
CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
ASO Academy Sports
$23.70 /

+1.28 (+5.71%)

10/27/20
Fly Intel: Top five analyst initiations
10/27/20 UBS
Academy Sports initiated with a Buy at UBS
10/27/20 Credit Suisse
Academy Sports initiated with an Outperform at Credit Suisse
10/27/20 JPMorgan
Academy Sports initiated with an Overweight at JPMorgan
WSFS WSFS Financial
$46.04 /

-0.5 (-1.07%)

STLD Steel Dynamics
$38.37 /

-0.35 (-0.90%)

STAA Staar Surgical
$89.69 /

-1.69 (-1.85%)

QUMU Qumu
$8.11 /

-0.32 (-3.80%)

KRMD Koru Medical
$5.13 /

-0.06 (-1.16%)

JJSF J & J Snack Foods
$156.47 /

+3.58 (+2.34%)

IPAR Inter Parfums
$60.50 /

+1.41 (+2.39%)

IAC IAC
$202.84 /

+1.83 (+0.91%)

HXL Hexcel
$47.09 /

-1.235 (-2.56%)

GGG Graco
$74.74 /

-1.17 (-1.54%)

FUL H.B. Fuller
$50.80 /

-1.98 (-3.75%)

CR Crane
$78.60 /

-2.15 (-2.66%)

BDGE Bridge Bancorp
$27.19 /

-0.08 (-0.29%)

BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

ASO Academy Sports
$23.70 /

+1.28 (+5.71%)

  • 28
    Jan
  • 26
    Jan
  • 26
    Jan
  • 28
    Jan
  • 20
    Jan
  • 11
    Dec
  • 02
    Oct
  • 14
    Aug
  • 19
    Jun
  • 28
    May
  • 12
    Mar
  • 11
    Feb
STLD Steel Dynamics
$38.37 /

-0.35 (-0.90%)

IAC IAC
$202.84 /

+1.83 (+0.91%)

HXL Hexcel
$47.09 /

-1.235 (-2.56%)

CVAC CureVac
$104.31 /

+2.31 (+2.26%)

QUMU Qumu
$8.11 /

-0.32 (-3.80%)

KRMD Koru Medical
$5.13 /

-0.06 (-1.16%)

IPAR Inter Parfums
$60.50 /

+1.41 (+2.39%)

IAC IAC
$202.84 /

+1.83 (+0.91%)

HXL Hexcel
$47.09 /

-1.235 (-2.56%)

FUL H.B. Fuller
$50.80 /

-1.98 (-3.75%)

CVAC CureVac
$104.31 /

+2.31 (+2.26%)

BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

ASO Academy Sports
$23.70 /

+1.28 (+5.71%)

STLD Steel Dynamics
$38.37 /

-0.35 (-0.90%)

KRMD Koru Medical
$5.13 /

-0.06 (-1.16%)

FUL H.B. Fuller
$50.80 /

-1.98 (-3.75%)

CVAC CureVac
$104.31 /

+2.31 (+2.26%)

BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

ASO Academy Sports
$23.70 /

+1.28 (+5.71%)

Hot Stocks
Sarissa Capital reports 5.0% passive stake in BioCryst » 16:46
01/25/21
01/25
16:46
01/25/21
16:46
BCRX

BioCryst

$9.15 /

-0.06 (-0.65%)

Sarissa Capital disclosed…

Sarissa Capital disclosed a 5.0% stake in BioCryst, which represents over 8.84M shares. The filing does not allow for activism.

ShowHide Related Items >><<
BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

12/22/20 JMP Securities
BioCryst selloff today a buying opportunity, says JMP Securities
12/07/20 H.C. Wainwright
BioCryst price target raised to $14 from $13 at H.C. Wainwright
12/04/20 Piper Sandler
BioCryst receives on-time approval with 'clean' label, says Piper Sandler
11/23/20 Evercore ISI
BioCryst initiated with an Outperform at Evercore ISI
BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

  • 28
    May
BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

BCRX BioCryst
$9.15 /

-0.06 (-0.65%)

Recommendations
Cantor says Amarin opportunity for Vascepa outside U.S. still 'underappreciated' » 16:03
01/25/21
01/25
16:03
01/25/21
16:03
AMRN

Amarin

$7.59 /

+1.025 (+15.63%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Louise Chen noted that the EU's CHMP published its agenda for meetings taking place this week, which includes reference to icosapent ethyl. The meeting timing puts Amarin in-line to "on the earlier side" of potentially receiving a CHMP opinion that it has said would occur in late January to early February of this year, according to Chen, who expects a positive CHMP opinion and for EMA approval to follow within 67 days of a CHMP decision. Chen, who thinks recent updates highlight the "underappreciated opportunities" for Vascepa outside of the U.S., keeps an Overweight rating on Amarin shares with a $10 price target.

ShowHide Related Items >><<
AMRN Amarin
$7.59 /

+1.025 (+15.63%)

AMRN Amarin
$7.59 /

+1.025 (+15.63%)

01/25/21 Piper Sandler
Piper Sandler reiterates 'conviction call' on Amarin into European decision
01/22/21 Cowen
Amarin remains undervalued under almost any scenario, says Cowen
01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
AMRN Amarin
$7.59 /

+1.025 (+15.63%)

AMRN Amarin
$7.59 /

+1.025 (+15.63%)

AMRN Amarin
$7.59 /

+1.025 (+15.63%)

AMRN Amarin
$7.59 /

+1.025 (+15.63%)

Recommendations
Piper Sandler reiterates 'conviction call' on Amarin into European decision » 08:46
01/25/21
01/25
08:46
01/25/21
08:46
AMRN

Amarin

$6.56 /

+0.255 (+4.04%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi reiterates reiterate her "conviction call" on Amarin's potential for European approval of Vascepa, with the Committee for Medicinal Products for Human Use opinion expected in late January or February. Potential European Medicines Agency approval 67 days after the CHMP recommendation is the most important stock-moving catalyst for Amarin shares in 2021, Rahimi tells investors in a research note. She continues to believe Amarin will have a "re-birth" in 202 on Vascepa's continued revenue growth and global market opportunity. The analyst keeps an Overweight rating on the shares with a $19 price target.

ShowHide Related Items >><<
AMRN Amarin
$6.56 /

+0.255 (+4.04%)

AMRN Amarin
$6.56 /

+0.255 (+4.04%)

01/22/21 Cowen
Amarin remains undervalued under almost any scenario, says Cowen
01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
12/23/20 Goldman Sachs
Amarin price target lowered to $6 from $8 at Goldman Sachs
AMRN Amarin
$6.56 /

+0.255 (+4.04%)

AMRN Amarin
$6.56 /

+0.255 (+4.04%)

AMRN Amarin
$6.56 /

+0.255 (+4.04%)

AMRN Amarin
$6.56 /

+0.255 (+4.04%)

Hot Stocks
Humana names Nwando Olayiwola, M.D., Chief Health Equity Officer » 08:38
01/25/21
01/25
08:38
01/25/21
08:38
HUM

Humana

$405.24 /

-10.09 (-2.43%)

Leading health and…

Leading health and well-being company Humana has named Nwando Olayiwola, M.D., MPH, FAAFP, to the position of Senior Vice President and Chief Health Equity Officer. In this newly created role, Dr. Olayiwola will report directly to Humana Chief Medical and Corporate Affairs Officer William Shrank, M.D., and will set direction and establish strategy to promote health equity across all Humana lines of business, including its care delivery assets. She will lead work to define enterprise-wide measures of equity, create goals for improvement and coordinate efforts to achieve them. In addition, Dr. Olayiwola will further Humana's focus on cultural sensitivity, ensuring that it's fully integrated into the design and development of Humana clinical programs, products, services and all member interactions and communications, while working collaboratively with the broader health care community to advance health equity so health care can work better for everyone, regardless of background, age or economic status. Dr. Olayiwola will assume the role effective April 5, 2021.

ShowHide Related Items >><<
HUM Humana
$405.24 /

-10.09 (-2.43%)

HUM Humana
$405.24 /

-10.09 (-2.43%)

01/13/21 Deutsche Bank
DaVita price target raised to $150 from $105 at Deutsche Bank
01/06/21 Argus
Humana price target raised to $450 from $430 at Argus
01/04/21
Fly Intel: Top five analyst upgrades
01/04/21
Humana upgraded to Outperform at RBC Capital on above-average MA growth
HUM Humana
$405.24 /

-10.09 (-2.43%)

HUM Humana
$405.24 /

-10.09 (-2.43%)

HUM Humana
$405.24 /

-10.09 (-2.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.